Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2025)

Crinetics Pharmaceuticals has reported Income from Continuing Operations over the past 9 years, most recently at 122635000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 52.16% year-over-year to 122635000.0; the TTM value through Dec 2025 reached 464954000.0, down 56.2%, while the annual FY2025 figure was 465317000.0, 56.18% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 122635000.0 at Crinetics Pharmaceuticals, up from 130091000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 22888000.0 in Q1 2021 and troughed at 130091000.0 in Q3 2025.
  • A 5-year average of 62145500.0 and a median of 53412000.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: fell 20.23% in 2023 and later tumbled 69.33% in 2025.
  • Year by year, Income from Continuing Operations stood at 30808000.0 in 2021, then plummeted by 48.18% to 45652000.0 in 2022, then fell by 22.53% to 55936000.0 in 2023, then plummeted by 44.08% to 80595000.0 in 2024, then plummeted by 52.16% to 122635000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CRNX at 122635000.0 in Q4 2025, 130091000.0 in Q3 2025, and 115657000.0 in Q2 2025.